Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 1;21(5):1173–1180. doi: 10.1038/s41436-018-0311-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Clinical management of FH-associated variant carriers. (a) Disease diagnoses in familial hypercholesterolemia (FH)-associated variant carriers before and after the study. After clinical and imaging-based phenotyping, 37 participants were diagnosed with FH: 3 carried FH diagnosis before the study (crossed lines), 21 participants were reclassified from having nonspecific hypercholesterolemia to FH (left-leaning diagonal lines), and 13 were newly diagnosed cases (right-leaning diagonal lines). (b) Statin treatment in FH-associated variant carriers before and after the study. At the initial appointment, 13 (32%) participants reported statin use, while 28 (68%) did not. At the end of the study moderate-intensity statin treatment was started for 14 (34%), and up-titrated to or kept on high-intensity statin treatment for 13 (32%) carriers. Statin treatment was not started for 14 (34%) participants, including 8 who either had contraindications or declined.